Zobrazeno 1 - 5 of 5 pro vyhledávání: '"Thomas Regenbogen"'
1
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
Autor: David J. Kuter, Merlin Efraim, Jiri Mayer, Marek Trněný, Vickie McDonald, Robert Bird, Thomas Regenbogen, Mamta Garg, Zane Kaplan, Nikolay Tzvetkov, Philip Y. Choi, A.J. Gerard Jansen, Milan Kostal, Ross Baker, Jaromir Gumulec, Eun-Ju Lee, Ilona Cunningham, Isaac Goncalves, Margaret Warner, Ralph Boccia, Terry Gernsheimer, Waleed Ghanima, Olga Bandman, Regan Burns, Ann Neale, Dolca Thomas, Puneet Arora, Beiyao Zheng, Nichola Cooper
Publikováno v: New England Journal of Medicine, 386(15), 1421-1431. Massachussetts Medical Society
BACKGROUND Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase, may increase platelet counts in patients with immune thrombocytopenia by means of dual mechanisms of action: decreased macrophage (Fcγ receptor)-mediated p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c172dc9093fbc35c4c4cf3aff5170e5c
https://doi.org/10.1056/nejmoa2110297
Zobrazit plný text záznamu
2
Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia
Autor: Dolca Thomas, Thomas Regenbogen, Zane Kaplan, Nichola Cooper, Regan Burns, Robert Bird, David J. Kuter, Merlin Efraim, Mamta Garg, Jiri Mayer, Ann Neale, Vickie McDonald, Olga Bandman
Publikováno v: Blood. 136:13-14
Introduction: Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton tyrosine kinase (BTK) that targets underlying disease mechanisms of platelet destruction without inhibiting platelet aggregation (common with ibrutinib). The mechanisms
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e726ea124133eb9241ec78709341d49f
https://doi.org/10.1182/blood-2020-134932
Zobrazit plný text záznamu
4
Review of Ongoing Clinical Trials in Non–Small-Cell Lung Cancer: A Status Report for 2012 from the ClinicalTrials.gov Web Site
Autor: Ramaswamy Govindan, Siddhartha Devarakonda, Janakiraman Subramanian, Alex R. Lane, Thomas Regenbogen, Gayathri Nagaraj, Gongfu Zhou
Publikováno v: Journal of Thoracic Oncology. 8(7):860-865
IntroductionClinical research in non–small-cell lung cancer (NSCLC) is a rapidly evolving field. In an effort to identify the current trends in lung cancer clinical research, we reviewed ongoing clinical trials in NSCLC listed in the ClinicalTrials
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dde8c4e2333b58d0d41606137f3297f8
Zobrazit plný text záznamu
5
Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer: A Status Report for 2009 from the ClinicalTrials.gov Website
Autor: Gongfu Zhou, Gayathri Nagaraj, Siddhartha Devarakonda, Ramaswamy Govindan, Thomas Regenbogen, Alex R. Lane, Janakiraman Subramanian
Publikováno v: Journal of Thoracic Oncology. 5(8):1116-1119
Introduction Several new agents are being tested in clinical trials for patients with non-small cell lung cancer (NSCLC). A survey of ongoing clinical trials in NSCLC in the ClinicalTrials.gov website would help identify areas that require further at
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40a16548e7fce1cb0f3a29f9cf4461c6
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje